Ehrlichia canis genes and vaccines

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/31 (2006.01) A61K 39/00 (2006.01) C07K 14/29 (2006.01) C12N 9/02 (2006.01) C12N 9/52 (2006.01)

Patent

CA 2375650

This invention provides the sequence of 5,300 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, ORF, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in this cloned fragment. The antigenic properties of these proteins allow them to be used to create a vaccine. An embodiment of this invention includes the creation of a DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine.

Cette invention concerne la séquence de 5300 nucléotides tirée du génome d'E. canis. Il existe 4 protéines, ProA, ProB, ORF, ainsi qu'un homologue de cytochrome oxydase, et un homologue partiel de peptidase signal lipoprotéique sur la terminaison carboxy, codées pour ce fragment cloné. Les propriétés antigéniques de ces protéines permettent leur utilisation pour créer un vaccin. Un mode de réalisation de cette invention comprend la création d'un vaccin à ADN, d'un vaccin recombiné et d'un vaccin à épitope de lymphocytes T.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Ehrlichia canis genes and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ehrlichia canis genes and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ehrlichia canis genes and vaccines will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1845777

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.